Stifel resumed coverage on Pyxis Oncology with a new price target
$PYXS
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/3/2025 | $9.00 | Buy | Stifel |
| 9/4/2025 | $5.00 | Buy | Guggenheim |
| 11/21/2024 | Outperform → Mkt Perform | William Blair | |
| 11/8/2024 | $13.00 | Overweight | Stephens |
| 8/8/2024 | $10.00 | Buy | Stifel |
| 5/7/2024 | $10.00 | Buy | Jefferies |
| 2/9/2024 | $8.00 | Buy | BTIG Research |
| 1/23/2024 | $12.00 | Outperform | Leerink Partners |
Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $5.00
William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
EFFECT - Pyxis Oncology, Inc. (0001782223) (Filer)
S-3 - Pyxis Oncology, Inc. (0001782223) (Filer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat.Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. – Fireside chat. Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website,
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 - Clinical update to focus on preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC patients, including from both post platinum & PD-1 and post EGFR & PD-1 arms, and preliminary data from Phase 1/2 combination dose escalation study of MICVO and KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC patients - Presented translational data at ESMO 2025 and AACR-NCI-EORTC providing meaningful insights into MICVO's first-in-concept non-cellul
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector. He joins Pyxis Oncology from Guggenheim Securities, where he served as Vice President of Equity Capital Markets, advising biotechnology clients on financing strategies and equity transactions. Pr
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel
SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp
- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20
- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected